WO2012100027A3 - Epigenetic biomarkers for liver disease - Google Patents

Epigenetic biomarkers for liver disease Download PDF

Info

Publication number
WO2012100027A3
WO2012100027A3 PCT/US2012/021835 US2012021835W WO2012100027A3 WO 2012100027 A3 WO2012100027 A3 WO 2012100027A3 US 2012021835 W US2012021835 W US 2012021835W WO 2012100027 A3 WO2012100027 A3 WO 2012100027A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cps1
transcription
phosphate synthetase
carbamoyl phosphate
Prior art date
Application number
PCT/US2012/021835
Other languages
French (fr)
Other versions
WO2012100027A2 (en
Inventor
Chen Liu
Hui-Jia Dong
Hongyan Liu
Original Assignee
University Of Florida Research Foundation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Florida Research Foundation, Inc. filed Critical University Of Florida Research Foundation, Inc.
Publication of WO2012100027A2 publication Critical patent/WO2012100027A2/en
Publication of WO2012100027A3 publication Critical patent/WO2012100027A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Methods are provided for identifying a hepatic cell exhibiting unregulated growth associated with methylation-silenced transcription of a carbamoyl phosphate synthetase 1 (CPS1) gene. In addition, methods of treating a cancer patient, wherein cancer cells in the patient exhibit methylation-silenced transcription of carbamoyl phosphate synthetase 1 (CPS1), are provided, as are reagents for practicing such methods. Additional methods are provided for identifying a colon cell exhibiting unregulated growth associated with transcription of a carbamoyl phosphate synthetase 1 (CPS1) gene. In addition, methods of treating a cancer patient, wherein colorectal cancer cells in the patient exhibit transcription of carbamoyl phosphate synthetase 1 (CPS1), are provided, as are reagents for practicing such methods.
PCT/US2012/021835 2011-01-19 2012-01-19 Epigenetic biomarkers for liver disease WO2012100027A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161434191P 2011-01-19 2011-01-19
US61/434,191 2011-01-19

Publications (2)

Publication Number Publication Date
WO2012100027A2 WO2012100027A2 (en) 2012-07-26
WO2012100027A3 true WO2012100027A3 (en) 2012-12-06

Family

ID=46516363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/021835 WO2012100027A2 (en) 2011-01-19 2012-01-19 Epigenetic biomarkers for liver disease

Country Status (1)

Country Link
WO (1) WO2012100027A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070128636A1 (en) * 2005-12-05 2007-06-07 Baker Joffre B Predictors Of Patient Response To Treatment With EGFR Inhibitors
EP2003453A2 (en) * 2006-03-29 2008-12-17 Yamasa Corporation Method for detection, determination or prediction of hepatic disorder
US20090181379A1 (en) * 2005-09-29 2009-07-16 Proyecto De Biomedicina Cima, S.L. Molecular markers of hepatocellular carcinoma and their applications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090181379A1 (en) * 2005-09-29 2009-07-16 Proyecto De Biomedicina Cima, S.L. Molecular markers of hepatocellular carcinoma and their applications
US20070128636A1 (en) * 2005-12-05 2007-06-07 Baker Joffre B Predictors Of Patient Response To Treatment With EGFR Inhibitors
EP2003453A2 (en) * 2006-03-29 2008-12-17 Yamasa Corporation Method for detection, determination or prediction of hepatic disorder

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BUTLER, S. L. ET AL.: "The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1.", LABORATORY INVESTIGATION., vol. 88, no. 1, January 2008 (2008-01-01), pages 78 - 88 *
LIU, H. ET AL.: "DNA methylation suppresses expression of the urea cycle enzyme carbamoyl phosphate synthetase 1 (CPS1) in human hepatocellular carcinoma.", AMERICAN JOURNAL OF PATHOLOGY., vol. 178, no. 2, February 2011 (2011-02-01), pages 652 - 661, XP002747488, DOI: doi:10.1016/j.ajpath.2010.10.023 *

Also Published As

Publication number Publication date
WO2012100027A2 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
WO2010048417A3 (en) Perfusion bioreactors, cell culture systems, and methods for production of cells and cell-derived products
WO2010018563A3 (en) Compositions and methods for the prognosis of lymphoma
WO2011072246A3 (en) Tal effector-mediated dna modification
WO2012031280A3 (en) Identification and enrichment of cell subpopulations
WO2010030365A3 (en) Thyroid tumors identified
WO2011156654A3 (en) Pathways characterization of cells
EP3539380A3 (en) Improved cell composition and methods of making the same
WO2010088633A3 (en) Novel cell lines and methods
WO2015108993A8 (en) Mutagenesis methods
IL210026A0 (en) Serum or plasma microrna as biomarkers for non-small cell lung cancer
WO2012006447A3 (en) Gene signatures for cancer prognosis
WO2013170170A3 (en) Compositions and methods for gene therapy
EP2292691A4 (en) Organic-inorganic complex dispersion, cell culture substratum manufactured by using the dispersion, and manufacturing methods for same
EP3683321A3 (en) Methods relating to circulating tumor cell clusters and the treatment of cancer
WO2010111659A8 (en) Tumor-initiating cells and methods for using same
WO2011112845A3 (en) Methods and compositions related to a multi-methylation assay to predict patient outcome
EP2601314A4 (en) Prognostic gene signatures for non-small cell lung cancer
WO2009102569A3 (en) Cell lines and methods for making and using them
WO2012135340A3 (en) Compositions and methods for diagnosing cancer
WO2013188469A3 (en) Pathways characterization of cells
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
WO2011097509A3 (en) Hypoxia-related gene signatures for cancer classification
WO2011160021A3 (en) Fullerene derivatives and photovoltaic cell containing them
WO2009149359A8 (en) Survival predictor for diffuse large b cell lymphoma
EP2210942A4 (en) Gene associated with liver cancer, and method for determination of the risk of acquiring liver cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12736109

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12736109

Country of ref document: EP

Kind code of ref document: A2